Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;480(1):75-89.
doi: 10.1007/s11010-024-04982-6. Epub 2024 Apr 6.

Emerging concepts on the FGF23 regulation and activity

María Angélica Rivoira  1 , María Elena Peralta López  1 , Vanessa Areco  1   2 , Gabriela Díaz de Barboza  1 , María Paula Dionisi  3 , Nori Tolosa de Talamoni  4
Affiliations
Review

Emerging concepts on the FGF23 regulation and activity

María Angélica Rivoira et al. Mol Cell Biochem. 2025 Jan.

Abstract

Fibroblast growth factor 23 (FGF23) discovery has provided new insights into the regulation of Pi and Ca homeostasis. It is secreted by osteoblasts and osteocytes, and acts mainly in the kidney, parathyroid, heart, and bone. The aim of this review is to highlight the current knowledge on the factors modulating the synthesis of FGF23, the canonical and non-canonical signaling pathways of the hormone, the role of FGF23 in different pathophysiological conditions, and the anti-FGF23 therapy. This is a narrative review based on the search of PubMed database in the range of years 2000-2023 using the keywords local and systemic regulators of FGF23 synthesis, FGF23 receptors, canonical and non-canonical pathways, pathophysiological conditions and FGF23, and anti-FGF23 therapy, focusing the data on the molecular mechanisms. The regulation of FGF23 synthesis is complex and multifactorial. It is regulated by local factors and systemic regulators mainly involved in bone mineralization. The excessive FGF23 production is associated with different congenital diseases and with diseases occurring with a secondary high FGF23 production such as in chronic disease kidney and tumor-induced osteomalacia (TIO). The anti-FGF23 therapy appears to be useful to treat chromosome X-linked hypophosphatemia and TIO, but there are doubts about the handle of excessive FGF23 production in CKD. FGF23 biochemistry and pathophysiology are generating a plethora of knowledge to reduce FGF23 bioactivity at many levels that might be useful for future therapeutics of diseases associated with high-serum FGF23 levels.

Keywords: Anti-FGF23 therapy; Canonical pathway; FGFRs; Local regulators; Non-canonical pathway; Pathophysiological conditions; Systemic regulators.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Vervloet M (2019) Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol 15(2):109–120. https://doi.org/10.1038/s41581-018-0087-2 - DOI - PubMed
    1. Murali SK, Roschger P, Zeitz U, Andrukhova KK, Erben ORG (2016) FGF23 regulates bone mineralization in a 1,25(OH)2D3 and klotho-independent manner. J Bone Miner Res 31(1):129–142. https://doi.org/10.1002/jbmr.2606 - DOI - PubMed
    1. Rausch S, Foller M (2022) The regulation of FGF23 under physiological and pathophysiological conditions. Pfügers Archiv Eur J Physiol 474:281–292. https://doi.org/10.1007/s00424-022-02668-w - DOI
    1. Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494–498. https://doi.org/10.1006/bbrc.2000.3696 - DOI - PubMed
    1. ADHR-CONSORTIUM (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348. https://doi.org/10.1038/81664 - DOI

Substances

LinkOut - more resources